Latest studies
- RecruitingPHASE3
Global Trial in APG2575 for Patients With CLL/SLL
This study is looking into a new treatment called lisaftoclax for people with a type of blood cancer called CLL/SLL. It compares adding lisaftoclax to an existing BTK inhibitor treatment versus just using the BTK inhibitor alone, for patients who have already been on BTK inhibitors.
CLL/SLLCzechia - RecruitingPHASE3
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
This study is looking at a new medicine called KAI-9531. It aims to see if weekly injections of this medicine can help people who are overweight or obese, and have other health issues related to their weight, lose weight. We want to know if it's safe and effective.
ObesityOverweightCzechia - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
This study looks at the long-term safety of a treatment called astegolimab for people with a lung condition called COPD. It's for people who have already taken part in previous studies of this drug.
Chronic Obstructive Pulmonary DiseaseCzechia - Active not recruitingPHASE3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
This study is looking into the long-term effects and safety of a medicine called mirikizumab for people with Crohn's disease. Participants have already taken part in a related study, and this new study will help us understand how the medicine works over a longer period.
Crohn's DiseaseCzechia - RecruitingPHASE2, PHASE3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
This study is testing a new medicine, CSL300, for adults with advanced kidney disease on dialysis. It aims to see if CSL300 can improve heart health and is safe, especially for those with existing heart conditions or diabetes.
End Stage Kidney DiseaseCzechia - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseCzechia - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseCzechia - RecruitingPHASE3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
This study is looking for better ways to treat advanced kidney cancer that has come back after earlier treatment. Researchers want to see if a new combination of medicines, belzutifan and zanzalintinib, works better than a standard medicine, cabozantinib, at shrinking the cancer.
Renal Cell CarcinomaCzechia - Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
Crohn's DiseaseCzechia - RecruitingPHASE3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
This study is for people with advanced bowel cancer that has spread and has a specific gene change called KRAS p.G12C. It compares a new combination of treatments to standard treatment to see if it can better stop the cancer from growing.
Metastatic Colorectal CancerCzechia - RecruitingPHASE2, PHASE3
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine, icotrokinra, for people in the UK with moderately to severely active Crohn's disease. Researchers want to see if it helps reduce symptoms and if it's safe to use, compared to a dummy medicine.
Crohn DiseaseCzechia - RecruitingPHASE3
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
This study looks at new drug combinations for advanced breast cancer. It compares saruparib and camizestrant with common existing treatments to see which works best for people with specific genetic changes (BRCA1, BRCA2, or PALB2m) in their cancer.
Advanced Breast CancerCzechia - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerCzechia - Active not recruitingPHASE3
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
This study compares two treatments, risankizumab and ustekinumab, for adults with moderate to severe Crohn's disease. Researchers want to see which treatment works best to reduce Crohn's symptoms. Both treatments are given initially by IV, then by injection.
Crohn's Disease (CD)Czechia - RecruitingPHASE3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new drug, Telisotuzumab Vedotin, against a standard treatment, Docetaxel, for advanced non-small cell lung cancer. It aims to see if the new drug works better and is safe for adults who have already had treatment.
Non Small Cell Lung CancerCzechia - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseCzechia - Active not recruitingPHASE3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called lutikizumab for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it helps reduce HS symptoms and is safe.
Hidradenitis SuppurativaCzechia - Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
Rheumatoid ArthritisCzechia - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study looks at the long-term effects and safety of a drug called mirikizumab for people with moderate to severe ulcerative colitis. It can last up to three years, with a chance to continue treatment afterward.
Ulcerative ColitisCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)
This study is testing a new medicine called Tozorakimab for people with severe COPD. It aims to see if Tozorakimab can reduce flare-ups and is safe to use long-term, compared to a dummy medicine.
Chronic Obstructive Pulmonary Disease (COPD)Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
This study looks at a new drug, pembrolizumab (Keytruda), combined with another medicine, enzalutamide. It's for men with advanced prostate cancer that has spread and isn't responding to hormone treatment. We want to see if this combination helps men live longer and slows down the cancer's growth.
Metastatic Castration-Resistant Prostate CancerCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ISIS 678354-CS6 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia
This study is testing a new medicine, Olezarsen, for people with very high levels of a type of fat in their blood called triglycerides. We want to see if it helps lower these levels and prevent related health problems.
Severe hypertryglyceridemiaCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized Phase 2 Study of Adjunctive EQU-001 for Uncontrolled Focal Onset Seizures
This study is testing a new medicine, EQU-001, for people with epilepsy whose seizures aren't fully controlled by their current treatment. It aims to see if the new medicine can reduce the number of seizures compared to a dummy medicine.
EpilepsyCzechia - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2/3, Multicenter, Randomized, Double blind, Placebo controlled Trial of the Safety and Efficacy of Flexible Doses of SEP 363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder.
This study is testing a new medicine, SEP-363856, for adults with major depression who are already taking antidepressants. It aims to see if adding this new medicine helps improve symptoms and if it's safe to use.
Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults.Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
This study is looking at a new medicine called Rocatinlimab for adults with moderate to severe eczema. We want to see if it helps improve skin, reduce itching, and is safe over 24 weeks compared to a dummy medicine.
Atopic DermatitisCzechia - Ongoing, recruitingPhase II and Phase III (Integrated)
Evasayil TM: A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome
This study is testing a new medicine, spesolimab, for Netherton syndrome. It's a trial where some people get the medicine and others get a dummy treatment (placebo) to see how well spesolimab works and if it's safe. We're looking at how it improves skin symptoms and overall well-being.
Netherton syndrome (NS)Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE MASKED, SHAM-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH UVEITIC MACULAR EDEMA
This study is testing a new eye injection to treat swelling in the eye caused by uveitis, a type of eye inflammation. It aims to see if the treatment improves eyesight and is safe for adults.
Uveitic Macular EdemaCzechia - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Single dose, open-label, laboratory blinded, randomised, 2-treatment, 2-period, 2-sequence, crossover bioequivalence study of test product Perampanel 12 mg film-coated tablets versus reference product Fycompa 12 mg film-coated tablets (Eisai GmbH) in healthy adult male and female subjects under fasting conditions.
This study compares two versions of the same medicine, Perampanel, to make sure they work the same way in the body. It's a small study in healthy adults, helping ensure new generic medicines are just as effective as their original counterparts.
Not applicable (submitted trial is a bioequivalence study in Healthy Subjects)Czechia - Ongoing, recruitingTherapeutic use (Phase IV)
Safety and efficacy of olanzapine treatment in psychosis: Effect of genetic and epigenetic factors – covariates of treatment response
This study looks at how a medicine called olanzapine works for people with psychosis. We want to understand if a person's genes or other natural body processes affect how well the treatment works and if they experience side effects. It’s for adults and focuses on how treatment is used in real life.
PsychosesCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ISIS 678354-CS9: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients with Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or with Severe Hypertriglyceridemia
This study is testing a new medicine, Olezarsen, for people with high 'triglycerides' (a type of fat in the blood) and heart problems. It aims to see if the medicine can lower these fats and is safe to use.
Hypertriglyceridemia, Cardiovascular Diseases, AtherosclerosisCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WHO Group 2)
This study is testing a new medicine, AZD3427, for people with heart failure and high blood pressure in the lungs caused by heart problems. We want to see if it improves how the heart and lungs work together.
Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WHO Group 2)Czechia - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase I study to evaluate the Pharmacokinetics and Safety of Letrozole LEBE in Healthy Post-menopausal Women.
This early study looks at a new form of a medicine called letrozole (LEBE) in healthy women who have gone through menopause. It aims to see how the body handles the medicine and if it's safe to use. This information helps us learn more about potential new treatments.
Healthy Post-menopausal women.Czechia - AuthorisedTherapeutic confirmatory (Phase III)
The effect of semaglutide therapy on hepatic fat content and on the acute reponse of liver fat to high-fat load in obese MASLD patients
This study looks at how a medicine called semaglutide affects fat in the liver of men with obesity and a condition called MASLD. We want to see if it reduces liver fat and how the liver responds to fatty foods after taking the medicine.
ObesityCzechia - Ongoing, recruitingTherapeutic use (Phase IV)
An 18-month low-interventional prospective, multicentre study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa
This study looks at how well different medicines (Elcocta and Alprolix) help people with haemophilia A or B protect their joints. Researchers will follow participants for 18 months to see if these treatments prevent joint problems.
Hemophilia A and BCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR)
This study is testing a new medicine, secukinumab, for polymyalgia rheumatica (PMR). It compares secukinumab with a dummy treatment (placebo) alongside a common steroid medicine to see if it helps reduce symptoms and allows people to use less steroid medicine.
Polymyalgia RheumaticaCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
This study is testing a new medicine, astegolimab, for people with a lung condition called COPD. It wants to see if this medicine can help reduce flare-ups (exacerbations) of COPD and if it's safe to use. You might get the new medicine or a dummy medicine.
Chronic Obstructive Pulmonary Disease (COPD)Czechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
This study is testing a new eye treatment called JNJ-81201887 for a condition called Geographic Atrophy (GA). GA is a serious eye problem linked to ageing that can cause blurry vision. Researchers want to see if this new treatment can slow down the worsening of GA.
Geographic AtrophyCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Randomized, Double-blind, Placebo- controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants with Moderate to Severe Plaque Psoriasis
This study is looking at a new tablet treatment called DC-806 for people with moderate to severe plaque psoriasis. Doctors want to see how well it works to clear skin and if it's safe compared to a dummy pill.
Plaque PsoriasisCzechia - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Randomized, Open-label, Single-Dose, Two-treatment, Two-period, Cross-over, Pivotal Bioequivalence Study Comparing Amoxicilin/Clavulanic acid powder for oral suspension 600 mg/42.9 mg/5 mL to Augmentin ES 600 mg/42.9 mg/5 mL powder for oral suspension in Healthy Adult Male and Female Volunteers under Fed Conditions.
This study compares a new liquid antibiotic to a well-known one. We want to see if the body handles both medicines in the exact same way when taken by healthy adults after eating. It helps make sure new versions of medicines work just as well.
Not applicable (submitted trial is a bioequivalence study in healthy subjects).Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension
This study looks at how long a special eye drop called Bimatoprost SR works for people with glaucoma or high eye pressure. It helps us understand if it keeps working over time to protect your eyesight.
Open-Angle Glaucoma, Ocular HypertensionCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, open-label, multi-center, 2-stage sequential cohort, dose escalation study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of subcutaneous SAR442501 in pediatric participants with Achondroplasia
This study is testing a new medicine for children with achondroplasia, a type of dwarfism. It's looking at whether the medicine, given by injection, is safe, how the body uses it, and if it helps with growth and other achondroplasia-related issues. It's an early-stage study.
OsteochondrodysplasiaCzechia - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Randomized, open-label, single dose, three-period, three treatment cross-over bioavailability study comparing test products Rosuvastatin/Ezetimibe, tablets, 20 mg /10 mg or Ezehron Duo, 20 mg + 10 mg, tablet, both administered in combination with Nilemdo 180 mg film-coated tablets to reference products Nustendi 180 mg/10 mg film-coated tablets in combination with Crestor, 20 mg, film-coated tablets in healthy male and female subjects under fasting conditions.
This study is testing different versions of cholesterol-lowering medicines to see how well they are absorbed by the body. It involves healthy men and women taking these medicines while doctors check their health closely.
not applicable (submitted trial is bioavailability study in healthy subjects)Czechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and safety of NNC6019-0001 at two dose levels in participants with transthyretin amyloid cardiomyopathy (ATTR CM).
This study is looking at a new medicine called coramitug for people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR CM). Researchers want to see if it helps improve how far people can walk and other heart health markers over about a year.
The present study will include a population of patients with established ATTR CM.Czechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Blinded, Placebo Controlled, Phase 2a Proof-of-Concept Study to Evaluate Efficacy, Safety, and Tolerability of GS-5718 in Participants with Cutaneous Lupus Erythematosus (CLE)
This study is testing a new tablet, GS-5718, for people with a skin condition called Cutaneous Lupus Erythematosus (CLE). We want to see if the drug helps reduce skin problems caused by CLE and if it's safe to use.
Cutaneous Lupus Erythematosus (CLE)Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)
This study looks at the long-term safety of a medicine called mavacamten for adults with a heart condition called hypertrophic cardiomyopathy. It follows people who have already taken part in previous studies of this medicine.
Hypertrophic cardiomyopathyCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled on inhaled corticosteroid and long-acting beta 2 agonist therapy
This study is testing a new medicine, RPT193, for adults with moderate to severe asthma that's not fully controlled by their usual inhalers. It aims to see how well RPT193 works and if it's safe, helping researchers understand if it could be a future treatment option.
AsthmaCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
This study looks at new ways to treat Hodgkin lymphoma, a type of cancer that affects the immune system. Researchers are testing different combinations of medicines to see how well they work and if they are safe. The main goal is to see if these treatments can make the cancer go away completely.
Classical Hodgkin LymphomaCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase 2b, randomised, double-blind, placebo-controlled, multi-site, parallel-group, dose finding trial to evaluate the efficacy and safety of different doses of subcutaneously administered LEO 138559 in adult subjects with moderate-to-severe atopic dermatitis (AD)
This study is testing a new medicine, LEO 138559, for moderate to severe eczema in adults. We want to see if different doses are safe and if they help improve eczema symptoms over 16 weeks compared to a dummy medicine.
Atopic DermatitisCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis
This study is testing a new medicine, JNJ-77242113, for people in the UK with moderate to severe ulcerative colitis. We want to see if it helps reduce symptoms and if it's safe compared to a dummy pill.
Ulcerative ColitisCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma
This study looks at a new inhaler, CHF6001, for people with asthma that isn't fully controlled. Researchers want to see if adding this new inhaler to their usual medication helps reduce asthma attacks over 52 weeks and is safe.
AsthmaCzechia